Evidence map›Paper›PMID 28486988›Full record

SynthesisFluids and barriers of the CNS2017

Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis.

Zhongyun Chen, Chunyan Liu, Jie Zhang, Norman Relkin, Yan Xing, Yanfeng Li

2 registry-linked trialsOpen access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Fluids and barriers of the CNS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05915000 recruitingnot on this mapstarted 2019, after this paper: background citation

Alterations of CSF Protein Markers as Prognostic Indicator of the Response to Cerebrospinal Fluid Shunting in Chronic Hydrocephalus in Adults

TypeobservationalSponsorUniversity of ValenciaRan2019 to 2029Enrolled150ConditionsBeta-amiloid and Phospho-tau Proteins in CSF, Ventricular Size After CSF Shunt, Cognitive Impairment and CSF Shunt, Motor Impairment Evolution After CSF ShuntArmsLumbar CSF protein marker determination
NCT06857136 completednot on this mapstarted 2021, after this paper: background citation

The Role of the Glymphatic System Avaluated Thourgh mr Imaging in the Diagnosis and Management of NPH

TypeobservationalSponsorFondazione I.R.C.C.S. Istituto Neurologico Carlo BestaRan2021 to 2024Enrolled29ConditionsHydrocephalus, Normal Pressure Hydrocephalus
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Association between p-tau181 in cerebrospinal fluid and shunt response in patients with normal-pressure hydrocephalus.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Zhongyun ChenDepartment of Neurology, Aviation General Hospital of China Medical University & Beijing Institute of Translational Medicine, Chinese Academy of Sciences, No. 3 Anwai Beiyuan Road, Chaoyang District, Beijing, 100012, China.
Chunyan LiuDepartment of Neurology, Aviation General Hospital of China Medical University & Beijing Institute of Translational Medicine, Chinese Academy of Sciences, No. 3 Anwai Beiyuan Road, Chaoyang District, Beijing, 100012, China.
Jie ZhangDepartment of Neurology, Aviation General Hospital of China Medical University & Beijing Institute of Translational Medicine, Chinese Academy of Sciences, No. 3 Anwai Beiyuan Road, Chaoyang District, Beijing, 100012, China.
Norman RelkinDepartment of Neurology and Neuroscience, Weill Medical College of Cornell University, Cornell Memory Disorders Program, 428 East 72 Street, Suite 500, New York, NY, 10021, USA.
Yan XingDepartment of Neurology, Aviation General Hospital of China Medical University & Beijing Institute of Translational Medicine, Chinese Academy of Sciences, No. 3 Anwai Beiyuan Road, Chaoyang District, Beijing, 100012, China. drxingyan@163.com.
Yanfeng LiDepartment of Neurology, Peking Union Medical College Hospital, Beijing, China. doctorliyf@163.com.
Aviation General Hospital · CNCornell University · USPeking Union Medical College Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe purpose of this systematic review and meta-analysis was to evaluate the performance of cerebrospinal fluid (CSF) beta amyloid 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) as potential diagnostic biomarkers for idiopathic normal-pressure hydrocephalus (iNPH) and to assess their utility indistinguishing patients with iNPH from those with Alzheimer disease (AD) and healthy normal controls.

methodsStudies were identified by searching PubMed, Embase, the Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Wanfang Chinese Periodical Database, VIP Chinese database, and Chinese Bio-medicine Database (CBM) before August 2016. The standardized mean difference (SMD) and 95% confidence interval (CI), comparing CSF Aβ42, t-tau, and p-tau levels between iNPH, AD and healthy controls, were calculated using random-effects models. Subgroup analyses were created according to ethnicity (Caucasian or Asian) and CSF type (lumbar or ventricular), and the publication bias was estimated using Egger's test and the Begg's test.

resultsA total of 10 studies including 413 patients with iNPH, 186 patients with AD and 147 healthy controls were included in this systematic review and meta-analysis. The concentrations of CSF t-tau, and p-tau were significantly lower in iNPH patients compared to AD (SMD = -1.26, 95% CI -1.95 to -0.57, P = 0.0004; SMD = -1.54, 95% CI -2.34 to -0.74, P = 0.0002, respectively) and lower than healthy controls (SMD = -0.80, 95% CI -1.50 to -0.09, P = 0.03; SMD = -1.12, 95% CI -1.38 to -0.86, P < 0.00001, respectively). Patients with iNPH had significantly lower Aβ42 levels compared with controls (SMD = -1.14, 95% CI -1.74 to -0.55, P = 0.0002), and slightly higher Aβ42 levels compared with AD patients (SMD = 0.32, 95% CI 0.00-0.63, P = 0.05). Subgroup analyses showed that the outcomes may have been influenced by ethnicity and CSF source. Compared to AD, overall sensitivity in differentiating iNPH was 0.813 (95% CI 0.636-0.928) for Aβ42, 0.828 (95% CI 0.732-0.900) for t-tau, 0.943 (95% CI 0.871-0.981) for p-tau. Relative to AD, overall specificity in differentiating iNPH was 0.506 (95% CI 0.393-0.619) for Aβ42, 0.842 (95% CI 0.756-0.907) for t-tau, 0.851 (95% CI 0.767-0.914) for p-tau.

conclusionThe results of our meta-analysis suggest that iNPH may be associated with significantly reduced levels of CSF Aβ42, t-tau and p-tau compared to the healthy normal state. Compared to AD, both t-tau and p-tau were significantly decreased in iNPH, but CSF Aβ42 was slightly increased. Prospective studies are needed to further assess the clinical utility of these and other CSF biomarkers in assisting in the diagnosis of iNPH and differentiating it from AD and other neurodegenerative disorders.

Indexed as

Diagnosis, DifferentialAmyloid beta-PeptidesDatabases, BibliographicHumansHydrocephalus, Normal PressurePeptide FragmentsPhosphorylationtau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-42)Peptide Fragmentstau ProteinsAlzheimer’s diseaseCSF biomarkersIdiopathic normal-pressure hydrocephalusMeta-analysisSystematic review

Identifiers

PMID28486988
PMCPMC5424383
OpenAlexW2610587026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.